Bladder cancer nursing: assessment, treatment, and NCLEX review

Bladder cancer ranks among the most common urologic malignancies in the United States, with an estimated 84,530 new cases in 2026, about 64,730 in men and 19,800 in women (American Cancer Society 2026; Siegel 2026). The disease disproportionately affects older men – the median age at diagnosis is 73 (NCI SEER, 2019–2023 data) – and carries a high recurrence rate that makes lifelong surveillance a clinical reality for most patients. Nursing students encounter bladder cancer on NCLEX through two high-yield scenarios: the management of intravesical BCG therapy (with its specific safety protocols around live bacteria), and the post-operative care of urinary diversions following radical cystectomy. This reference covers both, alongside the pathophysiology, staging, diagnostics, and treatment landscape needed to understand the clinical picture from presentation through follow-up.

Pathophysiology and histologic classification

The urothelium – the transitional epithelium lining the bladder, ureters, and renal pelvis – is the site of origin for the vast majority of bladder tumors. Urothelial carcinoma (also called transitional cell carcinoma, or TCC) accounts for approximately 90% of all bladder cancers in the United States. The remaining 10% are divided between squamous cell carcinoma (SCC, ~5%) and adenocarcinoma (~2%), with rare neuroendocrine and mixed histologies making up the rest.

The biologic distinction between histologic types matters clinically. Urothelial carcinoma arises from chronic mucosal irritation by carcinogens excreted in urine – the bladder serves as a reservoir, meaning the mucosa sits in prolonged contact with metabolized toxins. Squamous cell carcinoma carries a different epidemiologic fingerprint: it is associated with chronic parasitic infection (specifically Schistosoma haematobium, endemic in sub-Saharan Africa and the Middle East), long-standing urinary catheters, and recurrent bacterial infection. Adenocarcinoma is uncommon and typically arises from the urachal remnant or in patients with bladder exstrophy.

Superficial vs. muscle-invasive disease

The most clinically meaningful distinction in bladder cancer is whether the tumor has invaded the muscularis propria (detrusor muscle). This binary division – non-muscle-invasive (NMIBC) versus muscle-invasive (MIBC) – drives the entire treatment algorithm.

Non-muscle-invasive bladder cancer (approximately 75% of newly diagnosed cases, per the EAU 2026 guideline) is confined to the urothelium or lamina propria. It is treatable with organ-preserving surgery, but recurrence is common and depends heavily on risk group. In the EORTC risk tables, the probability of recurrence ranged from 15% to 61% at 1 year and from 31% to 78% at 5 years, and 5-year progression ranged from under 1% to 45% (Sylvester 2006). That spread is why surveillance intensity is set by risk group even after complete resection.

Muscle-invasive bladder cancer has breached the detrusor muscle. Left untreated, MIBC carries a median survival under two years. Standard care involves radical cystectomy (removal of the bladder) with urinary diversion – a major operation with profound nursing implications.

Metastatic disease involves regional lymph nodes (N1–N3) or distant organs (lungs, liver, bone, peritoneum) and requires systemic therapy.

AJCC/TNM staging and nursing implications

Risk factors

Understanding bladder cancer risk factors is high-yield for NCLEX and for patient education during primary prevention counseling.

Tobacco smoking is the single largest modifiable risk factor, accounting for approximately 50% of all cases (EAU 2026). Both current and former smokers carry elevated risk; risk declines after cessation but remains elevated for decades. Every bladder cancer patient should receive tobacco cessation counseling regardless of current smoking status.

Occupational exposures represent the second largest category. Workers historically exposed to aromatic amines – including aniline dyes, benzidine, and beta-naphthylamine – carry significantly elevated lifetime risk. Affected industries include rubber manufacturing, textile dyeing, leather tanning, hairdressing, and aluminum smelting. The latency period between exposure and diagnosis can be 20–50 years.

Chronic bladder irritation from specific causes predisposes to distinct histologic subtypes. Schistosoma haematobium infection (common in endemic regions of Africa and the Middle East) causes chronic mucosal inflammation and is the leading cause of squamous cell carcinoma worldwide. Chronic indwelling urinary catheters and recurrent urinary tract infections (particularly those with urease-producing organisms causing struvite stone formation) also carry elevated SCC risk. See the UTI nursing reference for clinical detail on urinary infections.

Cyclophosphamide, an alkylating chemotherapy agent, produces the metabolite acrolein, which accumulates in urine and directly irritates the urothelium. Patients who have received cyclophosphamide for prior malignancies or rheumatologic conditions carry an elevated risk of bladder cancer that rises with cumulative dose. In a case-control study of non-Hodgkin lymphoma survivors, overall risk was about 4.5-fold, rising to roughly 6-fold at 20–49 g and 14.5-fold at 50 g or more (Travis 1995). Concurrent mesna (2-mercaptoethane sulfonate) is administered with high-dose cyclophosphamide to bind acrolein in the urine and reduce bladder toxicity.

Demographic factors: male sex (the 2026 ACS estimates give a male-to-female case ratio of about 3.3:1), White race, and age older than 55 years are established risk factors. The elevated male risk is partly explained by occupational exposure patterns and higher historical smoking rates, though hormonal differences may also play a role.

Clinical presentation

Hematuria – the cardinal symptom

Painless hematuria is the most common presenting sign of bladder cancer (DeGeorge 2017; EAU 2026), and visible hematuria is linked to a higher stage at diagnosis than microscopic hematuria. The absence of pain is the clinically important detail – it distinguishes bladder cancer from hematuria caused by nephrolithiasis (which is painful) or urinary tract infection (which is accompanied by irritative symptoms). In any patient older than 40–50 presenting with painless hematuria, bladder malignancy must be excluded before attributing the symptom to a benign etiology.

Microscopic hematuria (RBCs detected on urinalysis without visible discoloration) is also associated with bladder cancer, though it is less specific. Intermittent hematuria – episodes of bloody urine separated by periods of apparent normalcy – is characteristic of bladder cancer and should not be falsely reassuring.

Irritative voiding symptoms

Carcinoma in situ (CIS/Tis) and high-grade NMIBC classically present with irritative voiding symptoms: frequency, urgency, and dysuria. These symptoms are indistinguishable from a urinary tract infection or pyelonephritis, and bladder cancer is frequently misdiagnosed as recurrent UTI in older adults, delaying diagnosis. The clinical rule: hematuria plus irritative voiding symptoms in an older patient is bladder cancer until proven otherwise.

Advanced and metastatic disease

Locally advanced disease may produce flank or pelvic pain from ureteral obstruction, a palpable pelvic mass, lower extremity edema from lymphatic or venous obstruction, or rectal pressure from posterior extension. Bone metastases cause focal bone pain and carry a risk of pathologic fracture. Constitutional symptoms – weight loss, fatigue, anorexia – suggest systemic disease and advanced staging.

Diagnostic workup

Urinalysis and urine cytology

Urinalysis will typically reveal hematuria (gross or microscopic). Urine cytology – microscopic examination of exfoliated cells in voided or catheterized urine – is a useful adjunct for detecting high-grade disease. Cytology has high specificity (low false-positive rate) but poor sensitivity for low-grade tumors; a negative cytology does not exclude bladder cancer.

Cystoscopy with biopsy – gold standard

Cystoscopy is the gold standard for bladder cancer diagnosis. A flexible or rigid endoscope is passed into the bladder via the urethra, allowing direct visualization of the urothelium. Any visible lesion undergoes biopsy. Cystoscopy cannot be replaced by imaging or cytology alone for definitive diagnosis.

Nursing preparation for cystoscopy includes informed consent, patient education that the procedure involves a scope passed through the urethra, and explaining that some post-procedure hematuria and dysuria are expected and typically resolve within 24–48 hours.

CT urography

CT urography provides cross-sectional imaging of the kidneys, ureters, and bladder with contrast enhancement during the excretory phase. It is used to evaluate the upper urinary tract (which cannot be seen on cystoscopy), assess tumor extent, and screen for synchronous upper tract urothelial carcinoma. The EAU 2026 guideline puts that incidence at about 1.8% overall, rising to 7.5% for tumors in the trigone. See the AKI nursing reference for contrast nephropathy prevention and the CKD nursing reference for implications in patients with renal impairment.

TURBT – diagnostic and therapeutic

Transurethral resection of bladder tumor (TURBT) is performed under anesthesia. The cystoscope is advanced into the bladder, and a resectoscope loop removes all visible tumor. TURBT is simultaneously:

• Diagnostic: the resected specimen provides tissue for histologic staging (depth of invasion) and grade
• Therapeutic: for NMIBC, TURBT may constitute definitive surgical treatment

Adequate depth of resection to include muscularis propria is essential for accurate staging; superficial biopsies that miss muscle may understage T2 disease as T1, leading to undertreated muscle-invasive cancer. Post-TURBT hematuria is expected; patients are typically managed with continuous bladder irrigation (CBI) until urine clears.

Treatment by stage

Non-muscle-invasive disease (Ta, T1, Tis)

Initial treatment is TURBT. For patients at intermediate or high risk of recurrence or progression, adjuvant intravesical therapy is instilled directly into the bladder via urethral catheter after resection.

Intravesical BCG (Bacillus Calmette-Guérin) is the preferred adjuvant therapy for high-risk NMIBC, particularly CIS and high-grade T1 disease. BCG is a live attenuated strain of Mycobacterium bovis that induces a local immune response in the bladder mucosa, reducing recurrence and lowering progression risk. The specific nursing protocols for BCG are detailed in the next section. Newer options sit alongside BCG: durvalumab is now FDA-approved in combination with BCG for BCG-naive high-risk NMIBC (POTOMAC; Imfinzi label, 05/2026), and pembrolizumab is approved as monotherapy for BCG-unresponsive high-risk NMIBC with CIS when cystectomy is not chosen (Keytruda label). The 2026 AUA/SUO update also covers TAR-200 (Inlexzo), a gemcitabine-releasing intravesical system, and sequential gemcitabine–docetaxel for BCG-unresponsive disease (Clark 2026).

Intravesical chemotherapy (mitomycin C or gemcitabine) is used for low- to intermediate-risk disease or as an alternative when BCG is contraindicated or unavailable. A single immediate instillation of chemotherapy after TURBT is given within 24 hours – every trial of this approach used that window, and the EAU 2026 guideline recommends it. It works by destroying circulating tumor cells released during resection and ablating residual cells at the resection site. In an individual-patient-data meta-analysis it cut the 5-year recurrence rate from 59% to 45% (Sylvester 2016). It is omitted if bladder perforation is suspected or if bleeding requires bladder irrigation. Mitomycin C is an alkylating agent, so nurses handling it use hazardous-drug precautions (chemotherapy gloves and gown).

Muscle-invasive disease (T2 and above)

Radical cystectomy is the surgical gold standard for MIBC. In men, standard surgery removes the bladder, prostate, seminal vesicles, and pelvic lymph nodes (radical cystoprostatectomy). In women, the bladder, urethra, uterus, ovaries, and anterior vaginal wall are removed (anterior pelvic exenteration). Urinary diversion is required in all cases.

Neoadjuvant cisplatin-based chemotherapy (typically gemcitabine/cisplatin or dose-dense MVAC) given before cystectomy improves 5-year overall survival by about 5% in absolute terms (individual-patient-data meta-analysis, Vale 2005) and has long been standard for cisplatin-eligible patients with T2–T4a disease. Perioperative immunotherapy has since been added: durvalumab with neoadjuvant gemcitabine/cisplatin, continued as adjuvant durvalumab after cystectomy (NIAGARA; Imfinzi label), and enfortumab vedotin plus pembrolizumab given before and after cystectomy (Padcev label, revised 07/2026). Check the current NCCN version for regimen selection.

Bladder-preservation chemoradiation (concurrent cisplatin-based chemotherapy with external beam radiation) is an alternative for patients who decline cystectomy or are medically inoperable. Outcomes approach those of cystectomy in carefully selected patients. Nursing monitoring during chemoradiation includes radiation cystitis (hematuria, frequency, urgency), radiation proctitis (diarrhea, rectal bleeding), and cisplatin toxicity (nephrotoxicity, ototoxicity, myelosuppression, nausea).

Metastatic disease

Enfortumab vedotin plus pembrolizumab (EV-P) is now the preferred first-line systemic treatment for locally advanced or metastatic urothelial carcinoma, regardless of cisplatin eligibility. The EV-302 trial reported median overall survival of 31.5 months with EV-P versus 16.1 months with platinum-based chemotherapy, and median progression-free survival of 12.5 versus 6.3 months. Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 and carries a distinctive toxicity profile that nursing must monitor: hyperglycemia (including diabetic ketoacidosis, which can occur with or without pre-existing diabetes), pneumonitis, peripheral neuropathy, ocular surface disorders, and severe cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (boxed warning). The label calls for close glucose monitoring in patients with, or at risk for, diabetes or hyperglycemia and says to withhold the drug if blood glucose is above 250 mg/dL; many protocols check glucose before every dose.

Platinum-based combination chemotherapy remains a first-line option when EV-P is contraindicated or unavailable, and it retains a role in the perioperative setting. Two regimens have comparable efficacy:

• MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) – older regimen; significant toxicity (mucositis, myelosuppression, alopecia)
• Gemcitabine/cisplatin (GC) – preferred first-line option with similar efficacy and more favorable toxicity profile

Patients ineligible for cisplatin (impaired renal function, poor performance status, peripheral neuropathy, hearing loss) may receive carboplatin-based regimens.

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis are used first-line in combination with enfortumab vedotin and as monotherapy after platinum-based therapy:

• Pembrolizumab (anti-PD-1) – first-line in combination with enfortumab vedotin, perioperatively with enfortumab vedotin for MIBC, as monotherapy after platinum-based chemotherapy, and for BCG-unresponsive high-risk NMIBC with CIS
• Avelumab (anti-PD-L1) – switch maintenance after first-line platinum chemotherapy without progression, an approach that improves overall survival for patients who receive chemotherapy first

Nursing care for patients receiving checkpoint inhibitors centers on recognition and management of immune-related adverse events (irAEs). See the oncology nursing reference for irAE monitoring and management principles.

Chemotherapy and immunotherapy agents – key nursing considerations

BCG intravesical therapy – nursing priorities

BCG therapy deserves its own section because it involves unique safety considerations that frequently appear on NCLEX. BCG is a live attenuated strain of Mycobacterium bovis, the organism responsible for bovine tuberculosis. The live bacterial nature of the preparation creates specific handling, administration, and patient education requirements that distinguish BCG from conventional intravesical chemotherapy.

Indications and contraindications

BCG is indicated for intermediate- and high-risk NMIBC, including CIS, high-grade T1, and Ta with high-risk features (multiple tumors, large tumor, rapid recurrence). The US TICE BCG label covers CIS and the prophylaxis of Ta/T1 papillary tumors after TURBT, and is not recommended for TaG1 tumors unless they are high risk. In a meta-analysis of 24 trials (4,863 patients), BCG reduced the odds of progression by 27% (9.8% vs 13.8% progressed), with the benefit seen only in patients given maintenance BCG (Sylvester 2002). A standard course is 6 weekly induction instillations followed by maintenance.

When BCG must not be given or must be postponed (TICE label; EAU 2026):

• Symptomatic urinary tract infection, a febrile illness, or visible (gross) hematuria – postpone until resolved, because a damaged, bleeding mucosa lets live bacteria enter the bloodstream. EAU notes that leukocyturia, microscopic hematuria, and asymptomatic bacteriuria are not contraindications.
• Within 7–14 days of TURBT, biopsy, or a traumatic catheterization (the label says at least 1 week, EAU says the first 2 weeks)
• Immunosuppression (congenital or acquired immune deficiency, cytotoxic therapy, radiation, corticosteroids) – a label contraindication; EAU treats some immunosuppressed groups as relative contraindications
• Active tuberculosis; the label advises a PPD test before treatment and ruling out active TB in PPD-positive patients
• Pregnancy and breastfeeding are cautions on the US label (contraindications on the EU BCG-medac label)

Administration and retention protocol

Ask the patient not to drink fluids for 4 hours before treatment and to empty the bladder first. BCG is reconstituted in 50 mL of preservative-free saline, used within 2 hours, and instilled by gravity through a urethral catheter, which is then removed (TICE label). The patient retains the BCG for 2 hours, or voids sooner if unable to hold it. The label suggests repositioning every 15 minutes (left side, right side, back, abdomen) to maximize bladder surface contact.

After 2 hours, the patient voids sitting down to avoid splashing. BCG is excreted alive in the voided urine. Afterward, encourage extra fluids to flush the bladder.

Post-instillation hygiene (NCLEX high-yield)

Because BCG is a live mycobacterium, the TICE label instructs that for the 6 hours after each treatment, all voided urine is disinfected for 15 minutes with an equal volume of household bleach before flushing. The clock starts at the treatment, so every void in that 6-hour window needs the bleach step, including the first one. The EU BCG-medac label gives the same idea in kitchen terms (2 cups of household bleach added to the toilet, left 15 minutes), and adds hand and genital washing after voiding and condom use or abstinence for 1 week. Institutional instructions vary, so teach the patient the protocol your unit uses.

This detail is tested on NCLEX: every void in the first 6 hours after treatment gets bleach, left for 15 minutes before flushing, and the patient sits to void.

Safe handling for nurses

BCG is an infectious agent. NIOSH removed it from its hazardous-drug list in 2024 for that reason, while stating that it “should be handled appropriately” and that each facility must assess the hazards of infectious treatments itself. The TICE label calls for aseptic preparation in a separate area, ideally a biocontainment hood. If no hood is available, the preparer wears gloves, a mask, and a gown to avoid inhaling organisms or exposing broken skin. Parenteral drugs must not be prepared where BCG has been prepared, needlesticks must be avoided, and all equipment that touches BCG is disposed of as biohazardous waste.

BCG therapy nursing checklist

Radical cystectomy and urinary diversion

When the bladder is surgically removed, urine must be diverted from the ureters to an alternative reservoir or outlet. Three main diversion types are used, each with distinct patient care requirements that are heavily tested on NCLEX and in clinical rotations.

Urinary diversion comparison

Ileal conduit stoma care – nursing priorities

The ileal conduit is the most commonly performed urinary diversion and the one most frequently assessed on NCLEX. Key nursing points:

Stoma assessment. A healthy stoma is beefy red, moist, and slightly edematous in the immediate post-operative period. Edema peaks in the first 24–72 hours then resolves. A dark, dusky, or black stoma indicates ischemia and requires immediate surgical evaluation. Stoma color assessment is the single most critical assessment at each nursing encounter.

Urostomy output. Urine will be the primary output. The presence of mucus in urostomy drainage is expected and normal – the ileal segment retains its mucus-secreting capacity after isolation. Patients should be educated that mucus does not indicate infection or wound breakdown. Blood in the urostomy output in the immediate post-operative period may be normal (small amounts from anastomotic sites and resection margins); frank hematuria or large clots should be reported.

Ureteral stents. In the immediate post-operative period, small tubes (ureteral stents) may be visible emerging from the stoma – typically two fine catheters, one per ureter. These are expected, temporary, and placed intraoperatively to protect the ureteral anastomoses while healing occurs. They are not signs of a complication. They are typically removed in the early post-operative weeks, often before or at the first clinic visit, according to the surgeon’s protocol.

Peristomal skin. Urine lacks the digestive enzymes that make ileostomy output so caustic, but constant contact with the peristomal skin still causes maceration and dermatitis, and alkaline urine (often from infection) promotes crystal encrustation around the stoma (WOCN 2017). A properly fitting skin barrier and pouch system that creates a seal at the stoma base is essential. The barrier wafer should be cut to fit within 1/8 inch of the stoma edge.

Pouching system and output volume. The urostomy pouch should be emptied when one-third to one-half full to prevent the weight of urine from breaking the skin barrier seal. At night, the pouch is connected to a larger-volume leg or bedside drainage bag to allow uninterrupted sleep. Minimum acceptable urine output is 30 mL/hr (same standard as for any urologic post-operative patient).

Neobladder patients – specific education

Patients with orthotopic neobladders require thorough education before discharge. The neobladder lacks the neurologic connections of the native bladder – there is no sensation of normal bladder filling, and voiding does not occur reflexively. Patients must:

• Void on a timed schedule every 3–4 hours rather than waiting for urgency (which they will not feel normally, especially initially)
• Use Valsalva maneuver (bearing down abdominally) or Credé maneuver (manual suprapubic pressure) to initiate and maintain urine flow
• Learn intermittent self-catheterization for situations of incomplete emptying (a significant risk, particularly in women with orthotopic neobladder)
• Understand that nocturnal incontinence is common in the first 6–12 months – the neobladder does not contract reflexively during sleep; timed nocturnal voiding (setting an alarm) is often necessary

Mucus retention is a neobladder-specific complication. The ileal segment secretes mucus into the reservoir; if this mucus is not regularly expelled by voiding and catheterization, it can plug the urethra or reservoir outlet, causing acute urinary retention. Patients should increase fluid intake and consider periodic reservoir irrigation per urology protocol.

Post-radical cystectomy nursing priorities

The cystectomy patient is a major surgical patient. Standard post-operative assessments apply, with specific urologic monitoring layered on top.

Fluid and electrolyte monitoring. Ileal conduit and neobladder construction use bowel segments. The ileum absorbs chloride in exchange for bicarbonate when in contact with urine – in patients with ileal diversions, this can lead to hyperchloremic metabolic acidosis over time. Nursing should monitor serum bicarbonate and chloride in the post-operative period and during long-term follow-up. Patients with impaired renal function (reduced ability to compensate) are at highest risk. See the CKD nursing reference for acid-base monitoring principles. The AKI nursing reference covers post-operative acute kidney injury risk – a major concern in cystectomy patients given the surgical complexity and fluid shifts involved.

Urine output monitoring. Monitor bilateral ureteral stent outputs (often tracked separately in the immediate post-operative period) and total diversion output. Minimum output: 30 mL/hr. Falling output may indicate ureteral obstruction, anastomotic leak, or hypovolemia.

Pain management. Cystectomy is a major abdominal/pelvic surgery. Epidural analgesia or patient-controlled analgesia (PCA) are standard post-operative pain management modalities. Adequate pain control is essential for early ambulation, which is critical for DVT prophylaxis.

DVT prophylaxis. Bladder cancer patients undergoing radical cystectomy are at high risk for venous thromboembolism – major pelvic surgery, malignancy, and prolonged operative time each independently elevate risk. Nursing DVT prophylaxis measures include sequential compression devices (SCDs), early ambulation, and anticoagulation per protocol. See the DVT nursing reference for full prophylaxis and monitoring detail.

Bowel function. Because bowel is isolated for conduit or neobladder construction, a functional ileus is expected post-operatively. Patients receive bowel rest initially. Monitor for return of bowel sounds and passage of flatus before advancing diet.

Psychosocial care. Cystectomy and urinary diversion represent a profound body image change. Younger patients may face sexual dysfunction (erectile dysfunction in men from nerve injury; vaginal changes in women), altered continence, and the visible presence of a stoma. Nursing should proactively address body image concerns, involve the enterostomal therapy (ET) nurse specialist, and connect patients with ostomy support resources. Colorectal cancer nursing covers stoma care principles that apply across diversion types, including the comparison between colostomy and urostomy management.

Surveillance and recurrence

Bladder cancer surveillance protocols reflect the high recurrence rate of NMIBC – the disease is characteristically an ongoing condition rather than a cured cancer, even after complete surgical resection.

Surveillance cystoscopy by risk group (EAU 2026):

• Low risk: cystoscopy at 3 months; if negative, again 9 months later, then yearly for 5 years
• Intermediate risk, low-grade Ta: cystoscopy at 3 months; if negative, every 6 months for 2 years, then yearly up to 10 years
• High and very high risk (including high-grade intermediate-risk tumors): cystoscopy and urine cytology at 3 months; if negative, every 3 months for 2 years, every 6 months until 5 years, then yearly for life

High-risk patients also need regular upper tract imaging (CT urography) because upper tract tumors can develop separately from the bladder; the 2026 AUA/SUO update recommends upper tract imaging every 1–2 years for intermediate- and high-risk disease. Risk is reassigned at each recurrence. Patients after cystectomy for MIBC follow a separate imaging-based schedule for local and distant relapse.

Signs of recurrence to include in patient discharge education: hematuria (painless or otherwise), return of irritative voiding symptoms, new back or flank pain (possible ureteral recurrence or obstruction), and constitutional symptoms.

Patients should understand that cystoscopy is the detection method for a disease that recurs in up to three-quarters of higher-risk patients within 5 years (Sylvester 2006), so skipping it means a recurrence can go unnoticed until it has progressed. Attendance at surveillance appointments should be part of discharge counseling at every care encounter.

Nephrolithiasis and pyelonephritis remain diagnostic considerations in the surveillance setting – new hematuria or flank pain in a cystectomy patient should not be attributed to these benign causes without excluding recurrent cancer first. For patients with ileal diversions, the CKD nursing reference covers the chronic metabolic consequences of intestinal urinary diversion.

NCLEX review: high-yield tips

• Painless hematuria is the classic bladder cancer presentation – never attribute painless hematuria in an older adult to a benign cause without cystoscopic exclusion of malignancy.
• BCG is a live attenuated mycobacterium (M. bovis) – not a chemotherapy drug; it triggers an immune response in the bladder mucosa.
• After BCG instillation, the patient retains the solution for 2 hours in the bladder before voiding, then voids sitting down.
• BCG post-void protocol (TICE label): for the 6 hours after treatment, add an equal volume of household bleach to each void and wait 15 minutes before flushing.
• Systemic BCG infection is a life-threatening emergency: fever ≥38.5°C lasting more than 2–3 days, fever ≥103°F, or worsening systemic signs after BCG = stop BCG, evaluate urgently, and treat with 2 or more antimycobacterial drugs (BCG is resistant to pyrazinamide).
• Postpone BCG for symptomatic UTI, fever, gross hematuria, or within 1–2 weeks of TURBT, biopsy, or traumatic catheterization; do not give it to immunosuppressed patients or those with active TB.
• Mucus in the urostomy drainage bag is normal – the ileal conduit segment retains mucus-secreting goblet cells.
• Stoma color assessment is the priority stoma nursing assessment: beefy red and moist = healthy; dark, dusky, or black = ischemia → immediate surgical escalation.
• Ileal conduit patients develop hyperchloremic metabolic acidosis over time – the ileal mucosa exchanges Cl⁻ for HCO₃⁻ when in contact with urine.
• Neobladder patients do not sense filling and cannot void reflexively – they must void on a schedule using Valsalva or Credé, and learn intermittent catheterization for incomplete emptying.
• Cystoscopy with biopsy is the gold standard for bladder cancer diagnosis – CT and urine cytology are adjuncts, not replacements.
• TURBT is simultaneously diagnostic (provides tissue for staging) and therapeutic (removes visible tumor) – understand both roles.
• Muscle-invasive disease (T2+) = radical cystectomy (complete bladder removal), usually with perioperative systemic therapy – partial resection is not the standard approach.
• Non-muscle-invasive bladder cancer recurs often, so surveillance cystoscopy is scheduled by risk group – every 3 months for the first 2 years in high-risk disease, less often in low-risk disease.
• A single immediate post-TURBT chemotherapy instillation is given within 24 hours, and never when perforation is suspected.
• Schistosomiasis (S. haematobium) → squamous cell carcinoma of the bladder (not urothelial/TCC) – remember the histologic link.
• Enfortumab vedotin plus pembrolizumab is the preferred first-line regimen for advanced or metastatic urothelial carcinoma – monitor blood glucose closely, because hyperglycemia and DKA can occur in patients with no diabetes history, and the drug is held if glucose is above 250 mg/dL.
• Pembrolizumab is an immune checkpoint inhibitor approved for bladder cancer – monitor for irAEs across all organ systems (pneumonitis, colitis, hepatitis, endocrinopathy).
• Cyclophosphamide use is a risk factor for bladder cancer via acrolein metabolite – mesna is co-administered with high-dose cyclophosphamide to prevent urothelial damage.
• Ureteral stents visible at the stoma in the immediate post-operative period are normal and expected – they protect the ureteral anastomoses and are removed in the early post-operative weeks.
• BCG is an infectious agent: prepare it aseptically and discard everything it touches as biohazardous waste, and never prepare parenteral drugs in the same area.

Summary

Bladder cancer nursing requires competence across a wide clinical arc: recognizing the cardinal presenting sign (painless hematuria), understanding the staging system that drives treatment, managing the specific safety protocols of live BCG intravesical therapy, and providing expert post-operative care after radical cystectomy and urinary diversion. The high recurrence rate of non-muscle-invasive disease means that long-term nurse-patient relationships around surveillance are intrinsic to bladder cancer care – not an afterthought. For broader oncology nursing context, the oncology nursing reference covers cancer care principles applicable across disease sites. The prostate cancer nursing reference addresses other GU oncology scenarios including post-prostatectomy care and androgen deprivation therapy management.

References

1. Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA: A Cancer Journal for Clinicians. 2026;76(1). doi:10.3322/caac.70043

2. Holzbeierlein JM, Bixler BR, Buckley DI, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). Journal of Urology. 2024;212(1):3–10. doi:10.1097/JU.0000000000003981

3. Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology. 2021;79(1):82–104. doi:10.1016/j.eururo.2020.03.055

4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 3.2026 (version listing checked October 19, 2026). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417

5. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology. 2000;18(17):3068–3077. doi:10.1200/JCO.2000.18.17.3068

6. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. Journal of Clinical Oncology. 1999;17(10):3173–3181. doi:10.1200/JCO.1999.17.10.3173

7. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. Journal of Urology. 2002;168(5):1964–1970. doi:10.1016/S0022-5347(05)64273-5

8. Hautmann RE, Abol-Enein H, Hafez K, et al. Urinary diversion. Urology. 2007;69(1 Suppl):17–49. doi:10.1016/j.urology.2006.05.058

9. American Cancer Society. Key Statistics for Bladder Cancer. Last revised January 13, 2026. https://www.cancer.org/cancer/types/bladder-cancer/about/key-statistics.html

10. Wound, Ostomy and Continence Nurses Society. WOCN Society Clinical Guideline: Management of the Adult Patient With a Fecal or Urinary Ostomy – An Executive Summary. Journal of Wound, Ostomy and Continence Nursing. 2018;45(1):50–58. doi:10.1097/WON.0000000000000396

11. Powles T, Csőszi T, Özgüroğlu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncology. 2021;22(7):931–945. doi:10.1016/S1470-2045(21)00152-2

12. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New England Journal of Medicine. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683

13. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New England Journal of Medicine. 2003;349(9):859–866. doi:10.1056/NEJMoa022148

14. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Journal of Urology. 2000;163(4):1124–1129. doi:10.1016/S0022-5347(05)67707-5

15. Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. New England Journal of Medicine. 2024;390(10):875–888. doi:10.1056/NEJMoa2312117

16. Powles T, Park SH, Caserta C, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up. Journal of Clinical Oncology. 2023;41(19):3486–3492. doi:10.1200/JCO.22.01792

17. Oncology Nursing Society (ONS). Nursing Considerations for Bladder Cancer Survivorship Care. ONS Voice; October 2021. https://www.ons.org/publications-research/voice/news-views/10-2021/nursing-considerations-bladder-cancer-survivorship

18. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Bladder Cancer (median age at diagnosis 73, SEER 21 2019–2023). Accessed October 19, 2026. https://seer.cancer.gov/statfacts/html/urinb.html

19. Merck Sharp & Dohme LLC. TICE BCG (BCG live, for intravesical use) prescribing information. Revised 2/2026. DailyMed setid c9b74876-e665-442b-87ad-b7333bc9a67a. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9b74876-e665-442b-87ad-b7333bc9a67a

20. medac GmbH. BCG-medac powder and solvent for intravesical suspension: Summary of Product Characteristics. electronic medicines compendium (emc), last updated November 11, 2025. https://www.medicines.org.uk/emc/medicine/44239/spc

21. Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. Hazardous Drugs: NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 and Final Reevaluation Determinations for Liraglutide and Pertuzumab (section D.2, Bacillus Calmette-Guerin). Federal Register. 2024;89(245). December 20, 2024. https://www.federalregister.gov/documents/2024/12/20/2024-30456/hazardous-drugs-niosh-list-of-hazardous-drugs-in-healthcare-settings-2024-and-final-reevaluation

22. Gontero P (Chair), Baard J, Birtle A, et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). Update March 2026. EAU Guidelines Office, Arnhem, The Netherlands; 2026. ISBN 978-94-92671-32-5. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer

23. Clark PE, Holzbeierlein J, Chang SS, et al. 2026 Updates to the Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline. Journal of Urology. Published online September 4, 2026. doi:10.1097/JU.0000000000005280

24. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology. 2006;49(3):466–477. doi:10.1016/j.eururo.2005.12.031

25. Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa–pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? European Urology. 2016;69(2):231–244. doi:10.1016/j.eururo.2015.05.050

26. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. Journal of the National Cancer Institute. 1995;87(7):524–531. doi:10.1093/jnci/87.7.524

27. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (Vale CL). Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. European Urology. 2005;48(2):202–206. doi:10.1016/j.eururo.2005.04.006

28. DeGeorge KC, Holt HR, Hodges SC. Bladder cancer: diagnosis and treatment. American Family Physician. 2017;96(8):507–514. https://www.aafp.org/pubs/afp/issues/2017/1015/p507.html

29. Seagen Inc. PADCEV (enfortumab vedotin-ejfv) prescribing information. Revised 07/2026. DailyMed setid b5631d3e-4604-4363-8f20-11dfc5a4a8ed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed

30. AstraZeneca. IMFINZI (durvalumab) prescribing information, section 1.6 Bladder Cancer (POTOMAC and NIAGARA indications). Revised 05/2026. DailyMed setid 8baba4ea-2855-42fa-9bd9-5a7548d4cec3. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3

31. Merck Sharp & Dohme LLC. KEYTRUDA (pembrolizumab) injection for intravenous use, prescribing information, section 1.7 Urothelial Cancer. Revised July 2026. DailyMed setid 9333c79b-d487-4538-a9f0-71b91a02b287. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287

32. Pfizer Laboratories. Doxorubicin hydrochloride injection prescribing information (boxed warning: cardiomyopathy). DailyMed setid 1fd148fb-0fbc-4b6f-b790-23546fb46a71. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fd148fb-0fbc-4b6f-b790-23546fb46a71